News Nov 18, 2024 Alimentiv Partners on a New Alcoholic Hepatitis Phase 1b Clinical Trial September 2024 – Alimentiv is proud to partner on an exciting new Phase 1b clinical trial in severe alcohol-associated hepatitis, an area with high mortality… Read Now
Interview Jul 19, 2024 Expanding the Alimentiv Site Network: An Interview With Peter Westerveld The Alimentiv Site Network (ASN) is our worldwide network of gastrointestinal (GI) centers that collaborate with us. With an established global reputation for high-quality monitoring… Read Now
Publication May 14, 2019 What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn’s disease activity? Read Now
Publication May 14, 2019 Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease Read Now
Publication May 14, 2019 Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease? Read Now
Publication May 14, 2019 Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease Read Now
Publication May 14, 2019 IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn’s disease? Read Now
